MedTrace Logo

Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT

NCT00212017 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2018-08-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether an alpha-glucosidase inhibitor, a drug for the suppression of postprandial hyperglycemia, could reduce the recurrence of myocardial infarction in patients with impaired glucose tolerance (IGT) and old myocardial infarction.

Conditions

Interventions

DRUG

voglibose

BEHAVIORAL

diet and exercise therapy

Sponsors & Collaborators

  • Ministry of Health, Labor and Welfare (Japan)

    collaborator UNKNOWN

  • National Cerebral and Cardiovascular Center, Japan

    lead OTHER

Principal Investigators

  • Masafumi Kitakaze, MD, PhD · National Cerebral and Cardiovascular Center, Japan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2012-06-30
Completion
2017-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00212017 on ClinicalTrials.gov